Why This Landed on My Radar
Humana just pulled a 180 on Medicare Advantage benefit cuts and is now projecting 25% membership growth this year. That’s not a typo - 25%. When the second-largest MA player in the country reverses course this dramatically after months of industry hand-wringing about unsustainable benefits, it tells us something important about where the MA market is heading. And for those of us managing patient panels with significant MA populations, this shift has real implications for how we think about contracting and patient mix going forward.
Here’s What’s Going On
Humana initially signaled it would need to cut Medicare Advantage benefits due to mounting cost pressures - a move that echoed concerns across the MA industry about shrinking margins and unsustainable supplemental benefits. But they’ve now reversed that position entirely. Instead of pulling back, they’re leaning in hard, projecting their MA membership will surge 25% in 2026.
This is significant timing. The MA industry has been vocal about payment rate pressures from CMS, rising medical costs, and the need to trim benefits to maintain profitability. Yet Humana, one of the most MA-dependent insurers in the country, is betting big that growth - not retrenchment - is the play. Their CEO Jim Rechtin is essentially calling the industry’s bluff: they’re willing to absorb near-term margin pressure to capture market share while competitors are hesitating.
What changed? Likely a combination of stronger-than-expected 2026 enrollment numbers industry-wide, political signals about rate stability, and a strategic decision that market share matters more than short-term profitability when you’re the number-two player trying to keep pace with United.
What This Means for Your Practice
Here in Texas, this matters more than you might think. Medicare Advantage penetration keeps climbing - we’re seeing MA enrollment approaching 50% of Medicare beneficiaries in major metros like Houston and Dallas. Humana is already a major player here, and if they’re growing their membership by a quarter this year, your MA patient mix is likely shifting whether you’ve noticed it yet or not.
For independent practices, this creates a tension. On one hand, robust MA growth with stable benefits means our Medicare patients keep their supplemental coverage - dental, vision, transportation, even OTC allowances that help with medication adherence. That’s good for patient care. On the other hand, every patient who moves from traditional Medicare to an MA plan means we’re now dealing with prior authorizations, narrow networks, and risk adjustment documentation requirements that traditional Medicare never demanded.
The lack of Medicaid expansion in Texas makes this even more critical. Our revenue mix is already complicated - large uninsured population, dominant commercial players like BCBS Texas and United that squeeze rates, and now a rapidly expanding MA segment that pays differently and documents differently than traditional Medicare. When half your Medicare panel is in MA plans, your billing and clinical documentation workflows fundamentally change. Miss those HCC codes during your annual wellness visits? You’re leaving money on the table and potentially making your attributed population look healthier than they are, which hurts next year’s risk adjustment.
Humana’s aggressive growth also signals they’re confident in their ability to manage costs through their provider networks - which means they’ll be pushing harder on value-based arrangements, bundled payments, and quality metrics that affect your reimbursement. The TMA has been vocal about the administrative burden these plans create, but the reality is the market is moving this direction regardless. Practices that haven’t built systems to capture diagnosis codes accurately, track quality measures, and manage the prior auth workload are going to feel increasing pressure.
Key Takeaways
- Humana’s 25% MA growth means your Medicare patient mix is likely shifting faster than you realize - check your payer mix reports quarterly, not annually
- Risk adjustment documentation isn’t optional anymore - when MA approaches 50% of your Medicare panel, missed HCC codes directly impact revenue
- Prior authorization volumes will continue climbing - if you’re still managing this manually, you’re burning staff time and delaying care
- Value-based contracts will be the norm, not the exception - Humana needs to control costs on this growth, and that means pushing risk to providers
- The early movers who build efficient MA workflows now will have a competitive advantage when competitors are drowning in administrative burden
What Smart Practices Are Doing
The practices handling this well have already invested in systems that make risk adjustment documentation and quality measure tracking automatic rather than heroic. They’re using their annual wellness visits strategically, they’ve trained their MAs to flag diagnosis discrepancies, and they’re tracking their HCC capture rates like any other quality metric. They’re also being selective about which MA contracts they sign - not all plans are created equal, and margin matters.
Source
“Humana shifts stance on Medicare Advantage benefit cuts,” Modern Healthcare
Primary Care Perspective delivers curated intelligence from trusted healthcare sources.
© 2026 Primary Care Perspective | Texas Edition